Mynvax, a biotech business, has successfully completed an expanded Series A round led by Inviga Healthcare Fund, raising around Rs 21.63 crore ($2.6 million).
According to Mynvax’s regulatory filing retrieved from RoC, the board approved a special resolution to issue 5,127 Series A1 CCPS at an issue price of Rs 42,182 per share in order to raise Rs 21.63 crore.
Read also – DVARA KGFS Secures $10 Mn Debt Funding
Legacy Assets LLP contributed Rs 2 crore and Inviga Healthcare Fund invested Rs 15 crore. The remaining funds, albeit insignificantly, came from 27 additional investors.
Up to this point, Mynvax has funded between $9 and $10 million, including a $4.2 million Series A round led by Accel and including Lets Venture, 1Cword, Kotak Investments, and other investors.
The company has produced influenza shots as well as effective, thermotolerant vaccinations that guard against SARS-CoV-2 and its developing variations in recent years.
About Mynvax
Founded in 2017 by Dr. Gautham Nadig, Mynvax, a clinical-stage vaccine biotechnology company was founded with the singular vision of developing novel, improved, recombinant, thermostable vaccines to protect against respiratory viral infections.
Want to go deeper into the world of startups and entrepreneurship? Check out these categories on VIESTORIES:
Startup Success Stories: Discover inspiring tales of startups overcoming challenges and achieving success.
Funding Startup News: Stay updated with the latest news and trends in startup funding and investment.
Startup Insights: Dive into in-depth analyses of various industries and market trends to make informed business decisions.
